Response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher response (≥ 50% reduction in MADRS/HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… showed no clear difference in remission (clinician‐rated) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events within 48 hours post operation · women undergoing PPTL under local anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Number of women requiring rescue medication · women undergoing PPTL under local anaesthesia
Combination of intraperitoneal lidocaine instillation and… may leads to lower number of women requiring rescue medication compared with placebo (low certainty).
1 finding from 1 review
RR 0.11 [0.03, 0.42]
Studies not reported
Low
Gastrointestinal adverse events · patients (> 65 years) following hip fracture; patients with a recent stroke
It is very uncertain whether summary of findings table ‐ Protein changes side effects: at least one adverse gastrointestinal event compared with standard diet (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · long‐term care patients; inpatients without dehydration with energy intake by tube feeding; patients with pressure ulcers
It is very uncertain whether summary of findings table ‐ Energy, protein and micronutrients changes side effects: at least one adverse gastrointestinal event compared with standard diet (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · residents of long‐term care (≥ 65 years) with pressure ulcers; inpatients with pressure ulcers
It is very uncertain whether summary of findings table ‐ Protein, arginine, zinc and antioxidants changes side effects: at least one adverse gastrointestinal event compared with standard diet or placebo (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · malnourished patients with pressure ulcers
It is very uncertain whether summary of findings table ‐ Arginine and micronutrients changes side effects: at least one adverse gastrointestinal event compared with standard diet (very low certainty).
1 finding from 1 review
Adverse effects/events: at least 1 adverse effect ‐ as defined by individual studies. · adults with pressure ulcers
It is very uncertain whether summary of findings table ‐ Collagen changes side effects: at least one adverse event compared with standard diet or placebo (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Gabapentin changes risk for at least one adverse event per patient compared with pregabalin (very low certainty).
1 finding from 1 review
Risk for at least one adverse drug reaction (ADR) per participant · patients with chronic kidney disease (CKD) pruritus
Summary of findings table ‐ Kappa‐opioid agonists may leads to higher risk for at least one adverse drug reaction (ADR) per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Ondansetron changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per participant ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Cromolyn sodium changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
Summary of findings table ‐ Topical capsaicin may leads to higher risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · health problem or population
Summary of findings table ‐ GABA‐analogues showed no clear difference in risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · participants with cholestatic pruritus (CP)
It is very uncertain whether summary of findings table ‐ Rifampin/rifampicin changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per participant ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found